-
Russia hits Ukraine with deadly strikes as Zelensky denounces Moscow's 'cynicism'
-
EU urges US to stick to tariff deal terms
-
Hantavirus on the Hondius: what we know
-
Rahm eligible for Ryder Cup after deal with European Tour
-
Stocks rise, oil falls as traders eye earnings, US-Iran ceasefire
-
Bayern's Kompany channels 'inner tranquility' before PSG showdown
-
Colombian mine explosion kills nine
-
Matthews latest England World Cup-winner out of Women's Six Nations
-
Race to find port for cruise ship battling deadly rodent virus
-
Celtic's O'Neill says Hearts' rise good for Scottish football
-
Ethiopia and Sudan accuse each other of attacks
-
Injured Mbappe faces backlash over Sardinia trip before Clasico
-
Vodafone to take full ownership of UK mobile operator
-
Stocks advance, oil falls as traders eye US-Iran ceasefire
-
Sabalenka ready to boycott Grand Slams over prize money
-
Boko Haram attack on Chad army base kills at least 24: military, local officials
-
US trade gap widens in March as AI spending boosts imports
-
US threatens 'devastating' response to any Iran attack on shipping
-
Murphy warns snooker hopefuls to 'work harder' to match Chinese stars
-
Race to find port for hantavirus-stricken cruise ship
-
Romanian pro-EU PM loses no-confidence motion
-
Edin Terzic to become Athletic Bilbao coach next season
-
Borthwick backed by RFU to take England to 2027 Rugby World Cup
-
EU hails 'leap forward' in ties with Russia's ally Armenia
-
German car-ramming suspect had mental health problems: reports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
World body in dark over allegations against China badminton chief
-
Asian stocks drop amid fears over US-Iran ceasefire
-
China fireworks factory explosion kills 26, injures 61
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Ukraine pressures Russia as midnight ceasefire looms
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
P.Sousa--PC